Synovial sarcoma is a soft tissue sarcoma occurring at all ages. In the Netherlands, the standard treatment for localised disease in adults consists of radical surgery, with adjuvant radiotherapy on indication (marginal excision, R1 resection) or neo-adjuvant radiotherapy in case radical resection is deemed unattainable beforehand. Neo-adjuvant chemotherapy may be indicated when extensive down staging is necessary for the prospect of a radical resection. Adjuvant chemotherapy is mainly given within the context of a clinical trial, with a lack of convincing data substantiating survival benefit ([@bib7]). In paediatric patients, however, patients are treated according to international (European or Children\'s Oncology Group (COG)) non-rhabdomyosarcoma protocols as long as the children are candidates for such protocols and protocols are active at the time a patient presents with synovial sarcoma. The current epidemiological analysis reflects real-life management. Stage at diagnosis is a known prognostic factor, with a reported 69% 10-year cancer-specific survival in patients with local disease at diagnosis, dropping to 8.9% in patients with metastasis at diagnosis ([@bib11]). In addition to stage at diagnosis, several retrospective studies in patients with localised disease have looked at age as a prognostic factor for survival, with children having a more favourable outcome compared with adult synovial sarcoma patients. The association between age at diagnosis and survival has also been reported in a variety of other sarcomas ([@bib6]). The present retrospective nationwide study aimed to investigate a broader range of age groups, including elderly patients, thereby explicitly exploring whether other factors such as tumour size, tumour localisation, and treatment modalities modified age-related survival differences.

Patients and methods
====================

Data source and study population
--------------------------------

The data were obtained from the Netherlands Cancer Registry (NCR). Cases were registered following notification by the Dutch Pathology Network (PALGA), supplemented by annual record linkage with the national hospital discharge database. Information on patient (age at diagnosis and sex) and tumour characteristics (primary tumour site, histology, size, and date of diagnosis) as well as hospital characteristics and treatment modality (type of primary treatment and resection status) was collected from hospital records by trained registrars. Follow-up information on vital status was obtained through linkage with the Municipal Personal Records Database (GBA). We obtained consent for the design, data abstraction process, as well as storage protocols from the national supervisory committee of the NCR. All patients histologically diagnosed with synovial sarcoma between 1989 and 2013 were included. The diagnosis was based on the local pathologist\'s diagnosis, often complemented with histological review in regional sarcoma panels. No information on molecular markers, including the X;18 translocation, was available. For survival analyses, we only included patients diagnosed with localised disease at presentation. Patients who were not treated according to standard care (i.e., did not receive surgery as part of their primary treatment) were also excluded from the analyses, as they were considered unrepresentative. Patients were classified as children (\<18 years), adolescents and young adults (AYAs; 18--34 years), adults (35--64 years), and elderly (*⩾*65 years), as they reflect the current Dutch situation of oncological age groups in clinical care. Treatment was divided into (1) surgery only, (2) surgery and (neo-)adjuvant radiotherapy, with or without chemotherapy, (3) surgery and (neo)adjuvant chemotherapy, and (4) no surgical treatment at all. We defined patients receiving surgery combined with chemotherapy as a separate group. We expected this to be a common treatment option in children as adjuvant chemotherapy is not a standard treatment for adult synovial sarcoma patients in the Netherlands, and could therefore be of influence on age-related survival. Due to the small patient numbers, we were limited in our ability to define treatment groups. Consequently, we grouped together who received (neo)adjuvant radiotherapy and patients receiving (neo)adjuvant radio- and chemotherapy.

Data analyses and statistics
----------------------------

Distribution of descriptive characteristics over the age groups was evaluated with Chi-square tests. Crude survival rates, 5- and 10-year overall survival (OS), were calculated using the Kaplan--Meier method, and the log-rank test pooled over the strata was used to compare the OS curves. In addition, relative survival (RS) analyses were performed as an approximation of disease-specific survival ([@bib3]), with OS being corrected for expected mortality according to annual life tables of the general population matched on age, gender, and calendar year (annually retrieved from Statistics Netherlands).

To identify independent prognostic factors for survival, we developed Cox proportional hazards models for which factors were selected on the basis of both clinical plausibility and significance in univariable analyses (*P*\<0.1). In the multivariable analysis, we evaluated whether these factors modified the association between age and survival. Variables were considered confounders and included in the model on the basis of the log-likelihood test.

All statistical analyses were two-sided. Except for the selection of variables for the multivariable analysis, a *P*-value of \<0.05 was considered significant. Statistical calculations and survival curves were generated by using IBM SPSS Statistics version 20 (Armonk, NY, USA) and Stata 13.0 (Stata Corp, College Station, TX, USA). Missing data on histological subtype, tumour size, and tumour depth were considered missing at random, and were therefore imputed under fully conditional specification, using the MI command in Stata. On the basis of variables used in the regression analysis and those predictive of missing values, we generated 50 data sets using chains of 100 iterations. Convergence of the imputations was checked graphically, and the Cox models were built using both the imputed data set and the data set restricted to cases with complete data for comparative purposes.

Results
=======

In total, 613 synovial sarcoma patients were retrieved. At diagnosis, 461 patients (75.2%) were confirmed with localised disease ([Table 1](#tbl1){ref-type="table"}). Patients had a median age of 38.0 years (range 2--89). Surgery was performed in 416 (90.2%) of the patients, which was most often combined with radiotherapy (*n*=219, 47.5%). This group included patients who received both radio- and chemo-therapy (*n*=49). Surgery combined with chemotherapy alone was performed in a minority of the patients, although this treatment modality was provided three times more often in children (20.4%) than in the adult age groups (6.9% combined). Surgery was not undertaken in a minority of children (3.7%). Interestingly, this proportion was significantly higher in all adult patients (10.6%). Among the elderly, more than a quarter of patients did not undergo surgery (25.5%).

Compared with general hospitals, academic centres treated a significantly higher proportion of children (16.5% *vs* 7.3% *P*=0.005). In addition, academic centres more often treated larger tumours (56.9% *vs* 40.9% *P*=0.003) and tumours that were located deeply (54.6% *vs* 38.1% *P*=0.031).

Patients\' age showed a gradual decline in OS over the years. Overall, patients had a 5- and 10-year OS rate of 63.5±2.4% and 53.8±2.6%, respectively. Subdivided in the different age groups, the 5- and 10-year OS rates were \<18 years: 89.3±4.6% and 77.0±6.9%, 18--34 years: 73.0±3.8% and 64.0±4.3%, 35--64 years: 54.7±3.6% and 47.5±3.7%, and ⩾65 years: 43.0±7.0% and 28.4±7.1% (log-rank test: *P*\<0.001) ([Figure 1](#fig1){ref-type="fig"}). RS rates did not show large discrepancies with the estimates for OS except for the elderly: 5- and 10-year RS rates were 52.0% and 46.1%, respectively.

Univariable analyses ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}) identified age at diagnosis, tumour size, tumour depth, and site of origin as having a significant impact on the prognosis of synovial sarcoma patients (*P*\<0.1), and these factors were included in the multivariable analysis. In the multivariable analysis ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}), age turned out to be an independent prognostic indicator for OS, with increasing age at diagnosis contributing to a higher risk of death. Compared with children, AYAs had a hazard ratio (HR) of 2.29 (95% CI 1.10--4.77), while this was 4.10 for adults (95%CI 2.03--8.29) and 6.18 in the elderly (95% CI 2.83--13.49). In addition, patients with a larger tumour size did significantly worse compared with tumours ⩽5cm (HR 2.89; 95% CI 1.94--4.32). Considering the primary site, patients with their primary tumour located in the trunk had the worst prognosis (HR 2.07; 95% CI 1.39--3.07). Patients with their tumour located in the head or neck (HR 1.30; 95% CI 0.73--2.34) or other sites (HR 1.75; 95%CI 0.82--3.71) had similar survival rates as patients with a tumour in the extremity. Tumour depth had no significant impact (HR 1.44; 95% CI 0.80--2.62).

Discussion
==========

To our knowledge, this is the largest study reporting on age-related survival in synovial sarcoma patients with localised disease. Several smaller studies have attempted to demonstrate this age-related survival effect in patients with localised synovial sarcoma. Interestingly, almost none of these studies, all with different cutoff points, were able to detect a significant prognostic effect of age on patient outcome ([Table 2](#tbl2){ref-type="table"}). Nonetheless, a trend towards worse survival at higher age may be presumed, and our study demonstrated a significant survival difference across age groups in synovial sarcoma patients with localised disease at diagnosis. As no information was available on disease-specific survival, we also calculated RS rates to account for the general effect of age on mortality. The association of lower RS rates accompanying increasing age was also observed here. The drop in survival rates between 5 and 10 years across all age groups confirms the occurrence of late relapses in SS. In addition, the data show that this phenomenon occurs in all age groups.

The multivariable analysis identified older age, larger tumour size, and primary tumour localisation in the trunk as independent prognostic factors for worse OS in synovial sarcoma patients. As both tumour size and primary tumour localisation were equally distributed over the age groups, we do not believe that they accounted for the observed age-related survival effect.

Main limitations of this study concern the retrospective character of the data collection, and the long period over which data were resembled in which molecular diagnostics were first introduced and subsequently improved, which could have improved the final diagnostics. However, we do expect misdiagnosed cases to be evenly distributed across all age groups.

As this study is national-wide registry based, it is based on diagnosis made by pathologist from different hospitals, of whom many will not be sarcoma-dedicated. This could possibly explain the large proportion of pathology reports that lacked information on the synovial sarcoma subtype. The same is true with respect to residual disease status where reporting was inadequate in more than half of the surgical resections (51.9%). In addition, since the SYT-SSX translocation test has become a standard procedure only in recent years, translocations status is not yet included in the NCR database. As the first steps in sarcoma care centralisation have only been taking place in the Netherlands since 2012, improvements in pathology reporting are to be expected in the forthcoming years. Synovial sarcomas may well consist of hitherto undetermined subtypes, with different types occurring at different ages. Therefore, we hypothesise that tumour-genetic differences underlie the age effect, which has also been suggested in the study by [@bib9], who showed increased chromosome instability in adult *vs* paediatric synovial sarcoma patients.

In conclusion, our study demonstrated that outcomes of patients with synovial sarcoma significantly decrease with age regardless of primary tumour site, size, and treatment. However, none of the variables included in this study seems to provide an adequate explanation for the observed difference in survival. The results of this study are of utmost importance when designing future clinical studies for localised synovial sarcoma, taking age as a prognostic factor into account. Further exploration of differences in tumour biology between different age groups may aid in adapting new treatments directed at tumour-specific characteristics.
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![**Kaplan--Meier survival curves.** The Kaplan--Meier curves of overall survival for (**A**) age, (**B**) primary tumour size, (**C**) primary tumour localisation, and (**D**) treatment.](bjc2015375f1){#fig1}

###### Patient characteristics -- Localised disease

  **Variable**                       **Total**      **After imputation**   **Children, \<18 years**   **Young adults, 18**--**34 years**   **Adults, 35**--**64 years**   **Elderly,** ⩾**65 years**   ***P*****-value, chi-square**
  ---------------------------------- ------------- ---------------------- -------------------------- ------------------------------------ ------------------------------ ---------------------------- -------------------------------
  Number of patients                 461 (100%)                                   54 (11.7%)                     148 (32.1%)                       204 (44.3%)                    55 (11.9%)                          
  **Sex**                                                                                                                                                                                             
  Male                               248 (53.8%)                                  31 (57.4%)                      88 (59.5%)                        98 (48.0%)                    31 (56.4%)                       0.168
  Female                             213 (46.2%)                                  23 (42.6%)                      60 (40.5%)                       106 (52.0%)                    24 (43.6%)                          
  **Histology**                                                                                                                                                                                       
  Monophasic                         103 (22.3%)          (48.3%)                15 (53.3%)\*                    34 (43.7%)\*                      41 (47.3%)\*                  13 (59.3%)\*                      0.496
  Biphasic                           109 (23.6%)          (51.7%)                14 (46.7%)\*                    44 (56.3%)\*                      43 (52.7%)\*                  8 (40.7%)\*                          
  Unknown                            249 (54.0%)                                                                                                                                                                      
  **Tumour size**                                                                                                                                                                                     
  ⩽5 cm                              183 (39.7%)          (45.2%)                16 (43.7%)\*                    73 (53.8%)\*                      76 (41.7%)\*                  18 (36.3%)\*                      0.107
  \>5 cm                             208 (45.1%)          (54.8%)                18 (56.3%)\*                    60 (46.2%)\*                     100 (58.3%)\*                  30 (63.7%)\*                         
  Unknown                            70 (15.2%)                                                                                                                                                                       
  **Tumour depth**                                                                                                                                                                                    
  Superficial                        102 (22.1%)          (48.8%)                8 (46.5%)\*                     37 (52.1%)\*                      44 (46.0%)\*                  13 (52.9%)\*                      0.832
  Deep                               110 (23.9%)          (51.2%)                9 (53.5%)\*                     35 (47.9%)\*                      54 (54.0%)\*                  12 (47.1%)\*                         
  Unknown                            249 (54.0%)                                                                                                                                                                      
  **Site of origin**                                                                                                                                                                                  
  Extremities                        303 (65.7%)                                  35 (64.8%)                     107 (72.3%)                       129 (63.2%)                    32 (58.2%)                       0.161
  Head and neck                      39 (8.5%)                                    8 (14.8%)                       11 (7.4%)                         15 (7.4%)                      5 (9.1%)                           
  Trunk                              86 (18.7%)                                   10 (18.5%)                      23 (15.5%)                        39 (19.1%)                    14 (25.5%)                          
  Other[a](#t1-fn2){ref-type="fn"}   33 (7.2%)                                     1 (1.9%)                        7 (4.7%)                         21 (10.3%)                     4 (7.3%)                           
  **Primary treatment**                                                                                                                                                                               
  Surgery only                       158 (34.3%)                                  16 (29.6%)                      51 (34.5%)                        77 (37.8%)                    14 (25.5%)                      \<0.001
  Surgery+RT (+CT)                   219 (47.5%)                                  25 (46.3%)                      76 (51.4%)                        94 (46.1%)                    24 (43.6%)                          
  Surgery+CT                         39 (8.5%)                                    11 (20.4%)                      14 (9.5%)                         11 (5.4%)                      3 (5.5%)                           
  No surgery                         45 (9.8%)                                     2 (3.7%)                        7 (4.7%)                         22 (10.8%)                    14 (25.5%)                          
  **Hospital of surgery**                                                                                                                                                                             
  General hospital                   179 (43.0%)                                  13 (25.0%)                      59 (41.8%)                        87 (47.8%)                    20 (48.8%)                       0.026
  Academic hospital                  237 (57.0%)                                  39 (75.0%)                      82 (58.2%)                        95 (52.2%)                    21 (51.2%)                          
  No surgery performed               45                                                                                                                                                                               
  **Resection status**                                                                                                                                                                                
  R0/Rx                              361 (86.8%)                                  50 (96.2%)                     123 (87.2%)                       154 (84.6%)                    34 (82.9%)                       0.152
  R1/R2                              55 (13.2%)                                    2 (3.8%)                       18 (12.8%)                        28 (15.4%)                    7 (17.1%)                           
  No surgery performed               45                                                                                                                                                                               

Abbreviations: CT=chemotherapy; RT=radiotherapy.

The group 'other\' consisted of lung (*n*=14), mediastinum (*n*=8), (retro)peritoneum (*n*=5), kidney (*n*=3), stomach (*n*=2), and unknown (*n*=1).

###### Literature review age-related studies of synovial sarcoma patients with localised disease at diagnosis

  **Study**        **Nr of patients**   **Age groups**                     **Stage**                       **Outcome**      ***P*****-value**
  --------------- -------------------- ---------------- ----------------------------------------------- ------------------ -------------------
  Present study           461             \<18 years                   Localised disease                  5-year OS 89%       **\<0.001\***
                                                                                                          10-year OS 77%             
                                         18--34 years                                                     5-year OS 73%              
                                                                                                          10-year OS 64%             
                                         35--64 years                                                     5-year OS 55%              
                                                                                                          10-year OS 48%             
                                          ⩾65 years                                                       5-year OS 43%              
                                                                                                          10-year OS 28%             
  [@bib10]                250             \<18 years                   Localised disease                  5-year OS 89%          0.09\*
                                         18--65 years                                                     5-year OS 71%              
                                          \>65 years                                                      5-year OS 73%              
  [@bib5]                 215             \>16 years     Localised disease, with macroscopic resection   5-year OS 78.5%      Not reported
                                         17--30 years                                                    5-year OS 72.4%             
                                          \>30 years                                                     5-year OS 66.0%             
  [@bib8]                 150             \>20 years                   Localised disease                  10-year OS 69%       **0.04\***
                                          \>20 years                                                      10-year OS 54%             
  [@bib4]                 138             \<10 years                   Localised disease                  3-year OS 100%         0.7827
                                         10--21 years                                                     3-year OS 96%              
  [@bib13]                128             \>33 years                   Localised disease                 5-year DSS 66.9%         0.294
                                          \>33 years                                                     5-year DSS 58.7%            
  [@bib1]                 102             \>30 years                   Localised disease                 5-year EFS 70.9%         0.47
                                          \>30 years                                                     5-year EFS 68.6%            
  [@bib2]                  77             \>11 years                   Localised disease                  5-year OS 81%           0.60
                                         12--20 years                                                     5-year OS 80%              
  [@bib12]                 69             \<40 years                     Stage I--III                     5-year OS 63%           0.808
                                          \>40 years                                                      5-year OS 65%              
  [@bib14]                 51             \<20 years                   Localised disease                  5-year OS 100%       **0.042\***
                                          ⩾20 years                                                      5-year OS 55.2%             

Abbreviations: DSS=disease-specific survival; EFS=event-free survival; OS=overall survival; RR=relative survival.

\**P*-value based on the multivariable analysis. The significant *P*-values are highlighted in bold.
